Hedge funds are slowly warming up to the private markets in the health care, life sciences, and biopharma industries.
Several firms have either made more new investments this year than in 2022 or have come close to matching last year’s totals. This is significant given that the venture capital market in general, which peaked in late 2021 and early 2022, has a long road to recovery, especially among tech, internet, and consumer companies.
